Printer Friendly

Proteonomix gets CIR approval for Matrix NC-138.

M2 PHARMA-November 14, 2011-Proteonomix gets CIR approval for Matrix NC-138(C)2011 M2 COMMUNICATIONS

14 November 2011 - US biotechnology firm Proteonomix Inc (OTCBB:PROT) said on Friday its Matrix NC-138 cosmeceutical product had been cleared by the Cosmetic Ingredients Review Board (CIR) and had been issued an INCI name, thus enabling the company to commercialise the product in the USA.

The CIR approval and the assignment of an INCI nomenclature was given to Proteoderm Inc, a unit of Proteonomix, which has developed a series of anti-aging skincare products using a matrix of proteins (Matrix NC-138) initially discovered in non-embryonic stem cells.

The INCI name will enable the company to power ahead with the commercialisation of its cosmeceutical product, Proteoderm NC-138, in the US.

The CIR is an independent, non-profit panel of scientists and physicians established and funded by the Personal Care Products Council (formerly known as Cosmetic, Toiletry, and Fragrance Association (CTFA). The CIR makes an in-depth expert review and assessment of the safety of ingredients used in cosmetics in the US.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 14, 2011
Words:183
Previous Article:TetraLogic unveils results from Phase I study of TL32711.
Next Article:Azellon pockets GBP650,000 in financing round.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters